ProQR Therapeutics
ProQR Therapeutics [PRQR], based in Leiden, is a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. The company focuses drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.proqr.com
Related News
ProQR strengthens leadership with appointments of CFO and CMO to support next phase of growth
ProQR Therapeutics announces $8.1 million in new funding from Rett Syndrome Research Trust to expand RNA editing collaboration
ProQR appoints Peter A. Beal, PhD, as Chief ADAR Scientist
Lilly and ProQR to expand RNA editing collaboration
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.